Categories: News

JPMorgan ETFs (Ireland) ICAV: Change of Index for various sub-funds

DUBLIN, Ireland, Jan. 15, 2021 (GLOBE NEWSWIRE) —

JPMorgan ETFs (Ireland) ICAV

Notice of Index Change

Please note that effective 29 January 2021 the following Index Tracking Sub-Funds will change Index in order to retain the current index exit maturity rules and the Sub-Fund Supplements will be updated accordingly. There will be no change to how the Sub-Funds are managed in practice.

JPMorgan ETFs (Ireland) ICAV – BetaBuilders US Treasury Bond UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders US Treasury Bond 1-3 yr UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders UK Gilt 1-5 yr UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders EUR Govt Bond UCITS ETF
JPMorgan ETFs (Ireland) ICAV – BetaBuilders EUR Govt Bond 1-3 yr UCITS ETF

To view the full details, please paste the following URL into the address bar of your browser.

https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/supplemental/notice-to-shareholders/jpm-etfs-ireland-icav-index-changes-en.pdf

Enquiries:

JPMorgan
Annabel Dow
annabel.s.dow@jpmorgan.com
+44 207 7428379

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

29 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

29 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago